Abstract
We studied the combination of amphotericin B lipid complex (ABLC) and caspofungin in mice with disseminated Rhizopus oryzae. Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone.
MeSH terms
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / therapeutic use*
-
Caspofungin
-
Diabetes Mellitus, Experimental / microbiology
-
Diabetes Mellitus, Experimental / pathology
-
Diabetic Ketoacidosis / complications*
-
Diabetic Ketoacidosis / metabolism
-
Drug Combinations
-
Echinocandins
-
Lipopeptides
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Mucormycosis / drug therapy*
-
Mucormycosis / microbiology
-
Mucormycosis / mortality
-
Peptides, Cyclic / therapeutic use*
-
Phosphatidylcholines / therapeutic use*
-
Phosphatidylglycerols / therapeutic use*
-
Rhizopus*
-
Survival
Substances
-
Antifungal Agents
-
Drug Combinations
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Phosphatidylcholines
-
Phosphatidylglycerols
-
liposomal amphotericin B
-
Amphotericin B
-
Caspofungin